Referencias no citadas
(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30).
Recibido 28 Noviembre 2011
Aceptado 28 Noviembre 2011
Autor para correspondencia: R evista E spañola de C ardiología , Sociedad Española de Cardiología, Nuestra Señora de Guadalupe 5-7, 28028 Madrid, España. rec@revespcardiol.org
Bibliografía
[1]
Bermejo J, Segovia J, Alfonso F..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (New Orleans, Estados Unidos, 8-12 de noviembre de 2008)..
Rev Esp Cardiol. , (2009), 62 pp. 178-187
[2]
Segovia J, Bermejo J, Alfonso F..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Orlando, Estados Unidos, 28-31 de marzo de 2009)..
Rev Esp Cardiol. , (2009), 62 pp. 660-669
[3]
Heras M, Bermejo J, Segovia J, Alfonso F..
Resumen de los ensayos clínicos presentados en las sesiones científicas del Congreso de la Sociedad Europea de Cardiología (Barcelona, España, 29 de agosto-2 de septiembre de 2009)..
Rev Esp Cardiol. , (2009), 62 pp. 1149-1160
[4]
Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando, Estados Unidos, 14-18 de noviembre de 2009)..
Rev Esp Cardiol. , (2010), 63 pp. 190-199
[5]
Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Atlanta, Estados Unidos, 14-16 de marzo de 2010)..
Rev Esp Cardiol. , (2010), 63 pp. 695-707
[6]
Bayes-Genis A, Avanzas P, Pérez de Isla L, Sanchis J, Heras M..
Resumen de estudios clínicos presentados en el Congreso de 2010 de la European Society of Cardiology (28 de agosto-1 de septiembre de 2010, Estocolmo, Suecia)..
Rev Esp Cardiol. , (2010), 63 pp. 1292-1303
[7]
Avanzas P, Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Estados Unidos, 13-17 de noviembre de 2010)..
Rev Esp Cardiol. , (2011), 64
[8]
Avanzas P, Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M..
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Nueva Orleans, Luisiana, Estados Unidos, 2-5 de abril de 2011)..
Rev Esp Cardiol. , (2011), 64
[9]
Avanzas P, Bayes-Genis A, Pérez de Isla L, Sanchis J, Heras M..
Resumen de estudios clínicos presentados en el Congreso de 2011 de la European Society of Cardiology (27-30 de agosto de 2011, París, Francia)..
Rev Esp Cardiol. , (2011), 64
[10]
Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction [cited 16 Nov 2011]. N Engl J Med. 2011 Nov 16. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1109596?query=featured_home..
[11]
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Trial [citado 15 Nov 2011]. Disponible en: http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2654&sKey=46715a37-a068-4cc0-b37a-51568b3bd230&ckey=6c56085f-30f6-4ca3-9841-242b175fa8dd&mKey=%7bFA42FAFA-40B7-42EE-A779-1A1AF9DA6ECE%7d..
[12]
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome [citado 16 Nov 2011]. N Engl J Med. 2011 Nov 13. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1112277?query=featured_home..
[13]
Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: AIDA STEMI Trial [citado 15 Nov 2011]. Disponible en: http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2654&sKey=46715a37-a068-4cc0-b37a-51568b3bd230&ckey=52475fa4-5d7e-4b96-864e-5203d0bf1590&mKey=%7bFA42FAFA-40B7-42EE-A779-1A1AF9DA6ECE%7d..
[14]
Testing an evidence-based, individualized informed consent form to improve patients’ experiences with PCI [citado 15 Nov 2011]. Disponible en: http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2654&sKey=f0ac2a57-c80b-45c6-b3a0-ca44f81a6733&ckey=d454362f-c3d5-464a-ad5c-3cd41de70840&mKey=%7bFA42FAFA-40B7-42EE-A779-1A1AF9DA6ECE%7d..
[15]
Outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery: a randomized study [citado 15 Nov 2011]. Disponible en: http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2654&sKey=f0ac2a57-c80b-45c6-b3a0-ca44f81a6733&ckey=49931b1d-7156-417a-94a0-d8951a96a06d&mKey={FA42FAFA-40B7-42EE-A779-1A1AF9DA6ECE}..
[16]
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 or 300 mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death (ALPHEE) [citado 15 Nov 2011]. Disponible en: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_433343.pdf..
[17]
Atrial fibrillation catheter ablation versus surgical ablation treatment: a multicenter randomized clinical trial [citado 15 Nov 2011]. Disponible en: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_433344.pdf..
[18]
A randomized multicenter comparison of radiofrequency ablation and antiarrhythmic drug therapy as first-line treatment in 294 patients with paroxysmal atrial fibrillation [citado 15 Nov 2011]. Disponible en: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_433345.pdf..
[19]
Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation [cited 16 Nov 2011]. N Engl J Med. 2011 Nov 14. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1109867..
[20]
Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, et al. Colchicine reduces postoperative atrial fibrillation. Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) Atrial Fibrillation Substudy [cited 16 Nov 2011]. Circulation. 2011 Nov 16. Disponible en: http://circ.ahajournals.org/content/124/21/2290.abstract..
[21]
The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [cited 16 Nov 2011]. N Engl J Med. 2011 Nov 15. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1107579?query=featured_home..
[22]
Appel LJ, Clark JM, Yeh HC, Wang NY, Coughlin JW, Daumit G, et al. Comparative Effectiveness of weight-loss interventions in clinical practice [cited 16 Nov 2011]. N Engl J Med. 2011 Nov 15. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1108660..
[23]
Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease [cited 16 Nov 2011]. N Engl J Med. 2011 Nov 15. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1110874?query=featured_home&..
[24]
Nicholls SJ, Brewer HB, Kastelein JJP, Krueger KA, Wang, et-al..
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol [cited 16 Nov 2011]..
JAMA. , (2011), 306 pp. 2099-2109
[25]
Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Michele Toscano M, et al. Full coverage for preventive medications after myocardial infarction [cited 16 Nov 2011]. N Engl J Med. 2011 Nov 14. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMsa1107913?query=featured_home..
[26]
Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction [cited 15 Nov 2011]. Eur Heart J. 2011 Nov 14. Disponible en: http://eurheartj.oxfordjournals.org/content/early/2011/11/13/eurheartj.ehr433.long..
[27]
Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients [cited 15 Nov 2011]. N Engl J Med. 2011 Nov 13. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1110899..
[28]
Early surgery versus conventional treatment for infective endocarditis [cited 16 Nov 2011]. Disponible en: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_433351.pdf..
[29]
Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease. Six-month outcomes from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Study [cited 16 Nov 2011]. Circulation. 2011 Nov 16. Disponible en: http://circ.ahajournals.org/content/early/2011/11/15/CIRCULATIONAHA.111.075770.abstract..
[30]
Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease [cited 16 Nov 2011]. JAMA. 2011 Nov 16. Disponible en: http://jama.ama-assn.org/content/early/2011/11/09/jama.2011.1703.long..